Healthcare Revenue Cycle · Healthcare & Life Sciences
Should you build or buy 340B Compliance & Split-Billing Software?
340B Compliance & Split-Billing Software automates the real-time determination of which pharmacy dispensing events qualify for 340B pricing versus which must be billed at standard cost — managing accumulator logic, replenishment workflows, and the audit trail documentation that HRSA compliance reviews require.
The build-vs-buy decision for 340B Compliance & Split-Billing turns on how much the accumulator and replenishment logic is an engineering problem versus an audit-defensibility problem, and how prohibitive the liability of a failed HRSA compliance review is relative to the cost of a vendor contract; the specifics of your pharmacy mix and regulatory exposure decide it.
Build it, buy it, or bridge?
When building makes sense
Building 340B split-billing is theoretically possible but practically closed for most covered entities because the bar isn't accuracy — it's audit-defensibility. HRSA compliance audits require formal documentation of accumulator logic, replenishment history, and patient eligibility determinations in formats that have never been produced by an in-house build passing a real audit. The liability is serious: compliance failures can trigger repayment obligations and program termination. Each covered entity's patient eligibility rules, accumulator logic, and formulary configuration are genuinely institution-specific, and HRSA guidance changes regularly enough to demand dedicated compliance staff. The engineering challenge isn't the hardest part — maintaining that 340B engine through regulatory updates while keeping it audit-defensible is. The only organizations that might make a credible build case are those with extremely large program savings, a dedicated compliance team, and the regulatory relationships to validate their implementation.
When buying makes sense
Buying 340B split-billing software makes clear sense for covered entities because the vendor's value is audit-defensibility, not just software functionality. No independent team has shipped a production split-billing engine that passed an HRSA audit, and the liability attached to compliance failures — repayment obligations and program termination — makes that risk calculus decisive. Vendors like Macro Helix, Verity Solutions, and Sentry Data Systems absorb the HRSA regulatory update burden and provide the documented accumulator logic that auditors require. For most covered entities, 340B savings are millions of dollars annually — the software is the mechanism through which those savings are captured and defended. The question isn't really whether to buy but which vendor's accumulator logic best fits your pharmacy mix and how well their split-billing engine integrates with your specific dispensing system.
The desk read
340B split-billing is deeply institution-specific: each covered entity's patient eligibility rules, accumulator logic, formulary configuration, and audit-trail requirements are shaped by HRSA guidance that changes with some regularity. Vendors like Macro Helix, Verity Solutions, and Sentry Data Systems (Craneware) absorb the regulatory update burden and provide the audit-defensible documentation that HRSA compliance audits require. No independent team has shipped a production self-built 340B engine that passes HRSA audit, and the liability attached to compliance failures, potential repayment obligations and program termination, keeps the build path closed for most covered entities.
The strategic dimension here is financial, not competitive. 340B savings are a significant annual program for eligible hospitals and Federally Qualified Health Centers, often millions of dollars, and the software is the mechanism through which those savings are captured and defended. Buying earns its keep precisely because the audit-defensibility and the HRSA update responsiveness are inseparable from the product. The question for most organizations isn't build vs. buy but rather which vendor's accumulator logic best fits their pharmacy mix and how deeply their split-billing engine integrates with their specific pharmacy dispensing system.
Frequently asked
What is 340B Compliance & Split-Billing Software?
340B Compliance & Split-Billing Software automates the real-time determination of which pharmacy dispensing events qualify for 340B pricing versus which must be billed at standard cost — managing accumulator logic, replenishment workflows, and the audit trail documentation that HRSA compliance reviews require.
When does building 340B split-billing software make sense?
Building is effectively closed for most covered entities because no in-house implementation has passed an HRSA compliance audit — the barrier is audit-defensibility and liability exposure, not engineering capability. Only organizations with very large program savings, dedicated compliance teams, and regulatory validation capability might consider it.
When does buying 340B split-billing software make sense?
Buying makes sense for all covered entities because the vendor provides audit-defensible accumulator logic and absorbs HRSA update burden — both critical given the compliance stakes. For most organizations, 340B savings run into the millions annually, making vendor cost straightforward to justify.
What are the main 340B Compliance & Split-Billing vendors?
Representative vendors include Macro Helix (340B Architect), Sentry Data Systems / Craneware, SUNRx, Verity Solutions (Verity 340B). B4 Pro scores the full set.